ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2397 • ACR Convergence 2025

    Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France

    Guillaume Nardella1, Gerber Gomez2, Christian Fischer2 and Claire Monat1, 1Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, 2Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland

    Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
  • Abstract Number: 2382 • ACR Convergence 2025

    Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study

    Bana Shawareb1, Muhannad Haddadin1, lindsay Frumker2, Keri Ann Pfeil3, Meghan Gump3, Ansaam Daoud4 and Omer Pamuk5, 1Cleveland Clinic Akron General, Akron, OH, 2Case Western Reserve University, Cleveland, 3University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 4Case Western Reserve University/University Hospitals, Cleveland, OH, 5University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
  • Abstract Number: 2209 • ACR Convergence 2025

    Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS

    cristiana Sieiro1, Jose Ordas Martínez2, Ana Merino3, Helena Amar Muñoz4, Stefanie Burger5, Ignacio Braña Abascal5, Carmen Jose Mendéz6, Raquel Dos Santos Sobrín7, Jose Luis Puga Guzman7, Ricardo Blanco8 and Víctor Taboada Martínez3, 1Univrsity of Manchester, Manchester, United Kingdom, 2Complejo Asistencial Universitario de León, León, Spain, 3Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, 4Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, 5Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, 6Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, 7Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, 8Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
  • Abstract Number: 1931 • ACR Convergence 2025

    COSMOS Prevalence of aTTP in SLE

    Nisha Sapkota1, Yevheniia Andriushchenko2, Saadia Malik2, Sarang Choi2 and Sima Terebelo2, 1Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, 2Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse manifestations, including thrombotic thrombocytopenic purpura (TTP), a life-threatening hematologic disorder. The pathogenesis of…
  • Abstract Number: 1850 • ACR Convergence 2025

    First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses

    Rufei Lu1, Tayte Stephens2, Carla Guthridge1, Miles Smith1, Joseph Kheir1, Cristina Arriens1, Joan Merrill3, Marci Beel4, Susan Macwana1, Wade DeJager5, Nicholas Domingez1, Teresa Aberle1, Joel Guthridge1 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Science Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4Oklahoma Medical Research Foun, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal…
  • Abstract Number: 1830 • ACR Convergence 2025

    Single-Cell and Spatial Profiling Reveal Proinflammatory and Profibrotic Fibroblast-Macrophage Niches in Lupus Nephritis

    Chirag Raparia1, Paul Hoover2, Nir Hacohen3, Arnon Arazi4 and Anne Davidson1, 1Feinstein Institutes for Medical Research, Manhasset, NY, 2Brigham and Women's Hospital, Boston, MA, 3Broad Institute of MIT Harvard, Cambridge, MA, 4Feinstein Institutes for Medical Research, Acton, MA

    Background/Purpose: Lupus nephritis (LN) is a severe complication of SLE that can progress to chronic kidney disease, renal fibrosis, and eventual renal failure. Fibroblasts activated…
  • Abstract Number: 1719 • ACR Convergence 2025

    Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study

    Rusudan Tskitishvili1, Abdallah Hussein2, Nanuka Tsibadze3, Shatha Shahwan4 and Priju Varghese2, 1Virtua Health, Camden, NJ, 2Virtua Health, Camden, 3Jefferson Health - Einstein, Philadelphia, PA, 4Jordan University of Science and Technology, Jordan

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risks of cardiovascular events, renal complications, and premature mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown cardiorenal…
  • Abstract Number: 1640 • ACR Convergence 2025

    Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts

    Jessica Fitzpatrick1, Mrinalini Dey2, C. Barrett Bowling3, S. Sam Lim4, Courtney Hoge5, Charmayne Dunlop-Thomas5, Maria Dall'Era6, Patti Katz7, Jinoos Yazdany1 and Laura Plantinga8, 1UCSF, San Francisco, CA, 2Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 3Duke University, Durham, NC, 4Emory University School of Medicine, Atlanta, GA, 5Emory University, Atlanta, GA, 6Division of Rheumatology, University of California, San Francisco, CA, 7UCSF, San Rafael, CA, 8University of California, San Francisco, San Francisco, CA

    Background/Purpose: Physical function and performance are top priorities to individuals with systemic lupus erythematosus (SLE). Suboptimal physical function and performance are associated with disability, loss…
  • Abstract Number: 1541 • ACR Convergence 2025

    Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort

    Qizhi Yuan1, Qinli Qin2, Leyao Ma1 and Mengtao Li3, 1Peking Union Medical College Hospital, Beijing, China (People's Republic), 2Dongguan Kanghua Hospital, Dongguan, Guangdong, China (People's Republic), 3Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvements and recurrent relapses. The objectives of treatment include ensuring long-term patient survival, preventing…
  • Abstract Number: 1521 • ACR Convergence 2025

    Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data

    Brad Rovin1, William Pendergraft2, Liz Lightstone3, Eric Daugas4, Richard Furie5, Theodore Omachi2, Imran Hassan6, Elsa Martins7, Thomas Schindler7, Jay Garg2, Luis Quintana8, Piotr Leszczyński9 and Ana Malvar10, 1The Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, 4Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, 5Division of Rheumatology, Northwell Health, Great Neck, NY, 6Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 7F. Hoffmann-La Roche Ltd, Basel, Switzerland, 8Department of Nephrology, Hospital Clinic, Barcelona, Spain, 9Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, 10Organización Médica de Investigación, Buenos Aires, Argentina

    Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
  • Abstract Number: 1500 • ACR Convergence 2025

    Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study

    Milad Heydari-Kamjani1, Amir Daneshvar2, Dana Nachawati2, Elleson Harper2, Keri Ann Pfeil2, Meghan Gump2, Lindsay Frumker3 and Omer Pamuk1, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 3University hospitals Cleveland medical center, Highland Heights, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement…
  • Abstract Number: 1483 • ACR Convergence 2025

    Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls

    Fernanda M. Garcia-Garcia1, Oscar Azael Garza-Flores2, Esteban C. Garza-Gonzalez3, Rebeca L. Polina-Lugo4, Leslie Y. Lopez-Cantú1, Dionicio A. Galarza-Delgado1, Iris J. Colunga-Pedraza1, Jesus Alberto Cardenas-de la Garza5, Jose R Azpiri-Lopez6 and Victor M Fraga-Enriquez7, 1Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, 4Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 5Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 6Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 7Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and accelerated atherosclerosis, leading to increased cardiovascular (CV) risk. While CV…
  • Abstract Number: 1387 • ACR Convergence 2025

    Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network

    Jeffrey Curtis1, Emily Holladay2, Antton Egana3, Anjana Lalla3, Yujie Su4, Fenglong Xie5, Amy Mudano4, Shanette Daigle4 and Sara McCoy6, 1Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 2University of Alabama at Birmingham, Edmond, OK, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 5The University of Alabama at Birmingham, Birmingham, AL, 6University of Wisconsin–Madison, Madison, WI

    Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
  • Abstract Number: 1268 • ACR Convergence 2025

    Development of the LupusCoach Chatbot: Results of a Focus Group

    Leila Khalili1, Pooja Desai2, Maya Souvignier2, Adrienne Pichon2, Stephen Suh3, Alberto Nordmann-Gomes2, Lena Mamykina2 and Anca Askanase1, 1Columbia University Medical Center, New York, NY, 2Columbia University Irving Medical Center, New York, NY, 3Columbia University Irving Medical Center, New York City, NY

    Background/Purpose: Self-management education and coaching are successful interventions for managing chronic health conditions. However, accessibility of in-person coaching is limited; digital coaching is available and…
  • Abstract Number: 1070 • ACR Convergence 2025

    Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center

    Mahnoor Javed1, Deepak Jagannath2, Alma Aveytia Camacho3, Alwyn Mathew3, Konrad Harms3, Soudabeh Daliri3 and Myriam Guevara4, 1Houston Methodist, Richmond, TX, 2Houston Methodist Hospital, Sugar Land, TX, 3Houston Methodist, Houston, 4Houston Methodist, Houston, TX

    Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
  • 1
  • 2
  • 3
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology